Systemic Lupus Erythematous SLE Drugs Market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Report Description<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) is a chronic autoimmune disease which causes the<br />
immune system to mistakenly attack health body tissue. In <strong>SLE</strong>, body immune system can<br />
affect any part of the body, such as joints, organs, eyes, skin, etc. Often <strong>SLE</strong> can result in<br />
symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions,<br />
photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement,<br />
thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis,<br />
thrombosis, and myositis. It is also known as a disease of flare-ups and remissions and<br />
can range from mild to life threatening severity. It is also called as drug-induced lupus<br />
erythematosus due to common observation against drugs such as isoniazid, hydralazine<br />
and procainamide. Currently, there is no complete treatment for <strong>SLE</strong>. While only two<br />
biologic agents have been approved by FDA to treat <strong>SLE</strong>, synthetic drugs are still the<br />
mainstay of therapy in <strong>SLE</strong>. Based on available evidence, azathioprine and<br />
mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be<br />
considered an anchor drug in <strong>SLE</strong> because of the multiple beneficial effects of this agent.<br />
Browse Full Report@ http://www.futuremarketinsights.com/reports/systemic-lupuserythematous-sle-drugs-market<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Drivers & Restraints<br />
Global <strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> market is projected to grow due to high<br />
prevalence of autoimmune diseases particularly systemic lupus erythematous (<strong>SLE</strong>).<br />
Major drivers for global systemic erythematous drugs market are development of novel<br />
<strong>SLE</strong> therapies, increasing availability of bio similar drugs and increasing support for
Change language